IPSEN, OOO

Bylvay® (odevixibat) demonstrates sustained improvement in severe itch and serum bile acid levels in PFIC and ALGS patients, with data from PEDFIC 2 and ASSERT-EXT studies presented at AASLD 2024.

Ipsen presents Iqirvo data at AASLD 2024, showing sustained efficacy and safety in PBC patients over 3 years, with improvements in pruritus, fatigue, and sleep. Iqirvo is approved in the U.S., E.U., and U.K. for PBC treatment.

GENFIT presents pre-clinical data on ACLF treatments at The Liver Meeting 2024, including VS-01, SRT-015, CLM-022, and NTZ, and leads key ACLF events. The company anticipates data from four clinical trials by end of 2025, focusing on VS-01, NTZ, and SRT-015. GENFIT also presents NIS2+® data for MASH monitoring.

Tendinopathy market poised for growth due to increasing prevalence, awareness, and emerging treatments by companies like MiMedx, Novartis, Ipsen, and others. Key therapies include secukinumab, PRP, MSCs, corticosteroids, nitroglycerin patches, BPC-157, collagen hydrolysate, and hyaluronic acid. Market drivers include aging populations, sports participation, biologics advancements, and early diagnosis. Barriers include high therapy costs, limited awareness in developing countries, lack of standardized protocols, and competing therapies.

AI and new technologies are crucial for early detection and personalized treatment of breast and gynecological cancers, aiming to improve accessibility and outcomes, especially in resource-limited settings.

The Cervical Dystonia therapeutics market is evolving due to advancements, with emerging therapies like Daxibotulinumtoxin A and ABP-450. The 'Cervical Dystonia Pipeline Insight, 2024' report by DelveInsight provides a comprehensive evaluation of pipeline products, covering mechanisms of action, clinical studies, and NDA approvals. The report highlights key companies and therapies in the market, including Ipsen, Allerga, Medytox, Addex Therapeutics, and Revance Therapeutics.

Ipsen reports YTD 2024 total sales growth of 9.2% at CER, driven by Dysport, Cabometyx, and Bylvay. Regulatory approvals for Iqirvo and Kayfanda, and increased 2024 guidance: total-sales growth >8.0% at CER, core operating margin >31.0%.

Galderma announces phase III READY-4 trial data showing long-term safety of RelabotulinumtoxinA for frown lines and crow’s feet, with efficacy and patient satisfaction maintained across multiple treatments. The study met primary and secondary endpoints, with mild or moderate treatment-emergent adverse events reported by 18% of participants. RelabotulinumtoxinA, developed using PEARL™ Technology, is the first ready-to-use liquid neuromodulator optimized for simple volumetric dosing.